These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28449360)

  • 1. Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
    Winter RL; Saunders AB; Gordon SG; Miller MW; Fosgate GT; Suchodolski JS; Steiner JM
    Vet Clin Pathol; 2017 Jun; 46(2):299-307. PubMed ID: 28449360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease.
    Winter RL; Saunders AB; Gordon SG; Buch JS; Miller MW
    J Vet Cardiol; 2017 Apr; 19(2):124-131. PubMed ID: 28111138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration.
    Ruaux C; Scollan K; Suchodolski JS; Steiner JM; Sisson DD
    Vet Clin Pathol; 2015 Sep; 44(3):420-30. PubMed ID: 26108974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs.
    Ljungvall I; Höglund K; Tidholm A; Olsen LH; Borgarelli M; Venge P; Häggström J
    J Vet Intern Med; 2010; 24(1):153-9. PubMed ID: 20002554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical validation and clinical evaluation of a commercially available high-sensitivity immunoassay for the measurement of troponin I in humans for use in dogs.
    Winter RL; Saunders AB; Gordon SG; Miller MW; Sykes KT; Suchodolski JS; Steiner JM
    J Vet Cardiol; 2014 Jun; 16(2):81-9. PubMed ID: 24834862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease.
    Ljungvall I; Rajamäki MM; Crosara S; Olsen LH; Kvart C; Borgarelli M; Höglund K; Häggström J
    Am J Vet Res; 2011 Aug; 72(8):1022-8. PubMed ID: 21801058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
    Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease.
    Falk T; Ljungvall I; Zois NE; Höglund K; Olsen LH; Pedersen HD; Häggström J
    J Vet Intern Med; 2013; 27(3):500-6. PubMed ID: 23551840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
    Mangklabruks T; Surachetpong SD
    J Vet Cardiol; 2014 Sep; 16(3):155-62. PubMed ID: 25127665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease.
    Menciotti G; Borgarelli M; Aherne M; Wesselowski S; Häggström J; Ljungvall I; Lahmers SM; Abbott JA
    J Vet Cardiol; 2017 Apr; 19(2):113-123. PubMed ID: 28279678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P; Saengklub N; Limprasutr V; Sawangkoon S; Kijtawornrat A
    J Vet Med Sci; 2017 Sep; 79(9):1480-1488. PubMed ID: 28717064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cardiac troponin I concentration in dogs with precapillary and postcapillary pulmonary hypertension.
    Guglielmini C; Civitella C; Diana A; Di Tommaso M; Cipone M; Luciani A
    J Vet Intern Med; 2010; 24(1):145-52. PubMed ID: 20002552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
    Yu H; Lee D; Chae Y; Choi M; Lee Y; Yun T; Kang BT; Yang MP; Kim H
    Am J Vet Res; 2024 Jun; 85(6):. PubMed ID: 38531156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs.
    Ebisawa T; Ohta Y; Funayama M; Yamano S; Mizuno M; Mizuno T; Kasuya A; Sawada T; Lee J; Mizukoshi T; Uechi M
    Res Vet Sci; 2013 Jun; 94(3):717-21. PubMed ID: 23312500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1alpha as a marker for asymptomatic myxomatous mitral valve disease in dogs.
    Rasmussen CE; Sundqvist AV; Kjempff CT; Tarnow I; Kjelgaard-Hansen M; Kamstrup TS; Sterup AL; Soerensen TM; Olsen LH
    Vet J; 2010 May; 184(2):241-6. PubMed ID: 19324577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.